" "
Satellite Banner
Informatics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

CluePoints Cited in New FDA Guidance for Improved Data Quality

Published: Wednesday, August 14, 2013
Last Updated: Wednesday, August 14, 2013
Bookmark and Share
CSM techniques have been cited by the FDA in the recent release of the final guidance document detailing the agency's stance on the "Oversight of Clinical Investigations".

The guidance advocates the use of central monitoring to ensure the quality of clinical trial data and cites two papers written by the architects of CluePoints’ intelligent statistical algorithms that describe how these techniques can be used to effectively detect anomalies, and help improve the effectiveness of on-site monitoring by prioritizing site visits using central statistical data checks.1 

The new FDA guidance describes how central monitoring methodologies should be used, where appropriate, to oversee studies and effectively monitor clinical investigations to protect subjects and enhance the quality of research. The FDA also states that the previously preferred approach for regular on-site monitoring with 100% Source Data Verification (SDV) is no longer called for, particularly due to new technological advances that make it possible to monitor data quality more efficiently.

Not only do the CSM techniques offered by CluePoints play a crucial role in Risk-Based Monitoring, but they are used even more generally as part of a sponsor’s risk-mitigation strategy as they are extremely efficient at identifying data anomalies and, consequently, enhancing the quality of the final submission. Larger pharma sponsors are taking the clinical oversight advantage a stage further and are using CluePoints to ensure that their strategic outsourcing programs are not just getting them to database lock on-time and on budget, they are also safe in the knowledge that the quality and integrity of their clinical data is beyond reproach. They are running regular analyses of the clinical data throughout the study and charging their partners with taking corrective actions as discrepancies are identified.

The resulting efficiencies from undertaking CSM to target the sites identified ‘at risk’ are now being successfully harnessed by many sponsors and CROs alike. The savings that sponsors will enjoy from a comprehensive Central Monitoring approach will no doubt be significant in the medium-term, but even today sponsors can experience tangible cost benefits by reducing on-site monitoring efforts through targeting those sites that are deemed to be outliers using advanced statistical techniques to analyze the clinical trial data.

Marc Buyse, Founder of CluePoints commented, “This is a major step forward for our industry and one that all sponsors should embrace. The opportunity to improve data quality and integrity, while mitigating risk, is the outcome that everyone wants and the agency is encouraging an approach that not only does this but offers companies the opportunity to increase efficiencies and, ultimately, save a lot of money. CluePoints is delighted to be at the forefront of this initiative and is available to consult with anyone who is interested in the practical application of these techniques based on proven and validated experience to date”.

Francois Torche, CEO, CluePoints, says, “The agency’s guidance is recognition of an approach that the CluePoints team has been working towards for a number of years. We have a talented and enthusiastic group of experts that have been assisting sponsors to implement various approaches to Risk-Based Monitoring and the final guidance is a very close match to our overall vision. Subjective Key Risk Indicators based on operational metrics are of value but there is no doubt that an objective assessment of data quality is crucial to managing regulatory risk and ultimately reducing costs”.

Please see below for copies of the papers on Central Statistical Monitoring that are referenced in the FDA Guidance for Industry “Oversight of Clinical Investigations – A Risk-Based Approach to Monitoring” for the guidance itself.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
‘Lifespan Machine’ Probes Cause of Aging
Findings suggest that aging has no single mechanism.
Machine Learning Uncovers Unknown Bacterial Features
Technique robustly identified characteristic gene expression patterns in response to antibiotics, low oxygen conditions.
Nucleic Acid Computing Inside Cells
Using strands of nucleic acid, scientists have demonstrated basic computing operations inside a living mammalian cell.
Risk Map for Nematode Parasite in Uganda
Infection with the nematode parasite Mansonella perstans is one of the most neglected of the neglected tropical diseases.
DNA Analysis in the Fast Lane
Rice bioengineers' method should lead to better database of thermal behaviors.
Mapping out Cell Conversion
Researchers develop algorithm that takes the field of cell reprogramming forward.
Parallel Single-Cell Profiling
New single-cell genomics protocol allows researchers to study links between DNA modifications (methylation) and the activity of a gene.
ASCB: A CELLebration of Cell Biology
The last major congress of the year, ASCB is less a platform for launching new products, but one for confirming and consolidating the trends that have emerged over the past 12 months.
Three Glaucoma-Related Genes Discovered
NIH-funded genetics analysis of glaucoma is largest to date.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!